PL3423082T3 - Liraglutyd w schorzeniach sercowo-naczyniowych - Google Patents

Liraglutyd w schorzeniach sercowo-naczyniowych

Info

Publication number
PL3423082T3
PL3423082T3 PL17710160T PL17710160T PL3423082T3 PL 3423082 T3 PL3423082 T3 PL 3423082T3 PL 17710160 T PL17710160 T PL 17710160T PL 17710160 T PL17710160 T PL 17710160T PL 3423082 T3 PL3423082 T3 PL 3423082T3
Authority
PL
Poland
Prior art keywords
liraglutide
cardiovascular conditions
cardiovascular
conditions
Prior art date
Application number
PL17710160T
Other languages
English (en)
Polish (pl)
Inventor
Søren Rasmussen
Kajsa KVIST
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59723004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3423082(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of PL3423082T3 publication Critical patent/PL3423082T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
PL17710160T 2016-03-04 2017-03-03 Liraglutyd w schorzeniach sercowo-naczyniowych PL3423082T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP16158739 2016-03-04
EP16173917 2016-06-10
EP16001329 2016-06-13
US15/401,651 US9968659B2 (en) 2016-03-04 2017-01-09 Liraglutide in cardiovascular conditions
PCT/EP2017/054990 WO2017149112A1 (en) 2016-03-04 2017-03-03 Liraglutide in cardiovascular conditions
EP17710160.7A EP3423082B1 (en) 2016-03-04 2017-03-03 Liraglutide in cardiovascular conditions

Publications (1)

Publication Number Publication Date
PL3423082T3 true PL3423082T3 (pl) 2021-12-27

Family

ID=59723004

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17710160T PL3423082T3 (pl) 2016-03-04 2017-03-03 Liraglutyd w schorzeniach sercowo-naczyniowych

Country Status (24)

Country Link
US (2) US9968659B2 (enExample)
EP (1) EP3423082B1 (enExample)
JP (1) JP6940512B2 (enExample)
KR (1) KR102417455B1 (enExample)
CN (2) CN108778317A (enExample)
AU (2) AU2017225841A1 (enExample)
BR (1) BR112018067344A2 (enExample)
CA (1) CA3013532C (enExample)
CL (1) CL2018002515A1 (enExample)
DK (1) DK3423082T5 (enExample)
ES (1) ES2893755T3 (enExample)
HR (1) HRP20211492T1 (enExample)
HU (1) HUE055844T2 (enExample)
IL (1) IL261169B (enExample)
MA (1) MA43704A (enExample)
MX (1) MX394179B (enExample)
MY (1) MY195657A (enExample)
PH (1) PH12018501844B1 (enExample)
PL (1) PL3423082T3 (enExample)
RS (1) RS62501B1 (enExample)
RU (1) RU2745604C2 (enExample)
SI (1) SI3423082T1 (enExample)
WO (1) WO2017149112A1 (enExample)
ZA (1) ZA201805538B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
CN118987224A (zh) * 2020-12-16 2024-11-22 香港中文大学 一种治疗受试者的衰老相关脑功能障碍的组合物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808203A (en) 1997-05-12 1998-09-15 Medrad, Inc. Fluid pressure measurement devices
JP2005535569A (ja) * 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー/エス Glp−1アゴニスト及び心臓血管合併症
CN104826116A (zh) * 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
CN112618700A (zh) * 2004-11-12 2021-04-09 诺和诺德公司 促胰岛素肽的稳定制剂
WO2009030738A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
KR20110135411A (ko) 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ladaの治療に使用するためのdpp−4阻害剤としてのキサンチン誘導体
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
JP2016510795A (ja) 2013-03-15 2016-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用
JP6507154B2 (ja) 2013-06-14 2019-04-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及びその合併症を治療するためのddp−4阻害薬
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions

Also Published As

Publication number Publication date
JP6940512B2 (ja) 2021-09-29
CA3013532A1 (en) 2017-09-08
ES2893755T3 (es) 2022-02-10
MX394179B (es) 2025-03-24
CN108778317A (zh) 2018-11-09
PH12018501844B1 (en) 2023-03-17
DK3423082T3 (da) 2021-10-11
AU2024201937A1 (en) 2024-04-11
EP3423082B1 (en) 2021-08-04
IL261169A (en) 2018-10-31
CN116327897A (zh) 2023-06-27
DK3423082T5 (da) 2023-02-06
CL2018002515A1 (es) 2018-11-09
WO2017149112A1 (en) 2017-09-08
US20180236038A1 (en) 2018-08-23
PH12018501844A1 (en) 2019-05-15
HRP20211492T1 (hr) 2021-12-24
MX2018010097A (es) 2018-11-09
US20170252408A1 (en) 2017-09-07
US9968659B2 (en) 2018-05-15
RU2018134061A3 (enExample) 2020-07-15
RU2018134061A (ru) 2020-04-06
KR102417455B1 (ko) 2022-07-06
MY195657A (en) 2023-02-03
IL261169B (en) 2019-11-28
JP2019507174A (ja) 2019-03-14
AU2017225841A1 (en) 2018-08-23
HUE055844T2 (hu) 2021-12-28
CA3013532C (en) 2019-07-23
EP3423082A1 (en) 2019-01-09
ZA201805538B (en) 2020-05-27
MA43704A (fr) 2021-04-14
BR112018067344A2 (pt) 2019-01-08
KR20180114168A (ko) 2018-10-17
SI3423082T1 (sl) 2021-10-29
RS62501B1 (sr) 2021-11-30
RU2745604C2 (ru) 2021-03-29

Similar Documents

Publication Publication Date Title
PL3261455T3 (pl) Syropy allulozowe
GB201502197D0 (en) Interconnect
IL262390A (en) Semaglutide in cardiovascular conditions
GB201517368D0 (en) Value
IL256020B (en) Igfbp3 and uses thereof
IL248180A0 (en) Ionines are stable in the presence of hydroxide
GB201719541D0 (en) Cell Lines
PL3313757T3 (pl) Sortownik liniowy
GB201507032D0 (en) Allulose syrups
GB201521206D0 (en) Title in german
GB201521190D0 (en) Application in german
ZA201805538B (en) Liraglutide in cardiovascular conditions
GB201518745D0 (en) Buoyancy component
GB201416195D0 (en) Recreational Bobsleigh
SG11201802839VA (en) Sweetness enhancement
GB201523035D0 (en) In terferometry
PT3423082T (pt) Liraglutida em condições cardiovasculares
GB201521191D0 (en) Application in german
GB201514185D0 (en) Improvements in laptop cases
GB201508643D0 (en) Improvements in shirts
PT3448416T (pt) Semaglutido em condições cardiovasculares
GB201513676D0 (en) Inflatables / deflatables
GB201618109D0 (en) Improvements in drawing boards
GB2522268B (en) Recreational swing
GB201512547D0 (en) Washing lines